Pharma Pressreleases

This section covers the managerial aspects in the Pharma industry.

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Monday, February 20, 2017

Exelixis Inctoday announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors The primary endpoint of the trial is to determine the dose limiting toxicity DLT and recommended phase 2 doses o..

LYNPARZA™ (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer

Monday, February 20, 2017

AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA olaparib tablets 300mg twice daily to physicians choice of a standard of care chemotherapy in the treatment of patients with HER2negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutat..

Russian Government drive to increase domestic manufacturing fuelling growth at CPhI Russia

Monday, February 20, 2017

CPhI Russia IPhEB cphirussia returns to the Russian capital taking place at the JSC VDNH VVC Moscow 28th30th March as the Governments Pharma 2020 plan continues to stimulate demand for international pharmaceutical ingredients manufacturing and packaging equipment The events 4th edition will see th..

The Most Awaited Conference of Chicago – Drug Discovery and Development 2017

Saturday, February 18, 2017

Innovations and Advancements in Drug Discovery Changing the Topography of Pharmaceutical Industry Rapidly The demand for drug discovery technologies in the region of North America also gains from highincome population collectively promising healthy potential returns on investments due to high ado..

US FDA Expands Approval of Tiotropium Respimat® for Maintenance Treatment of Asthma in Children

Friday, February 17, 2017

Boehringer Ingelheim today announced that the US Food and Drug Administration FDA approved tiotropium Respimat marketed as SPIRIVA Respimat for the longterm oncedaily maintenance treatment of people with asthma aged 6 years and older who continue to experience symptoms despite their other maintenanc..

Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients

Friday, February 17, 2017

Ascendis Pharma AS a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases today announced the publication of its previously presented pediatric phase 2 trial of TransCon Growth Hormone in the Journal of Clinical Endocr..

Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx

Friday, February 17, 2017

Ionis Pharmaceuticals Incand Akcea Therapeutics a whollyowned subsidiary of Ionis Pharmaceuticals Inc announced today they have closed on their exclusive worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEAAPOaLRx and AKCEAAPOCIIILRx following clearance under..

Clintec marks 20th year of global clinical research with launch of new brand

Thursday, February 16, 2017

Clintec today announces the launch of its new brand identity reflected in their newly created website This in part marks Clintecs 20th anniversary and the achievement of significant milestones following another year of substantial growth together with a succession of key appointments that have enha..

Pharmapack Europe 2017 highlights new developments in pharma packaging and drug delivery

Thursday, February 16, 2017

Pharmapack Europe organised by UBM EMEA closed its 2017 edition celebrating its 20 years as the leading European event for pharmaceutical packaging and drug delivery devices The top trends that emerged from the twoday event included patient centricity traceability innovation compliance and adheren..

Sanaria's PfSPZ-CVac Vaccine Achieves High Level Protection Against Malaria in Clinical Trial

Thursday, February 16, 2017

In a report published today in Nature Sterile protection against human malaria by chemoattenuated PfSPZ vaccine investigators from the University of Tbingen reported all nine subjects 100 immunized with three doses of Sanaria PfSPZCVac malaria vaccine in a recently completed clinical trial were prot..

Pharma companies to grow overseas sales regionally at CPhI South East Asia

Thursday, February 16, 2017

CPhI South East Asia returns to the Jakarta International Expo in Indonesia for its sixth edition from the 22nd24th March 2017 as regional pharma companies expect robust growth The slowing pace of global markets and the increasing threat of a new protectionist wave is transforming the outlook of Sou..

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Wednesday, February 15, 2017

Hutchison China MediTech Limited ChiMed AIMNasdaq HCM and AstraZeneca PLC AstraZeneca will present data from the ongoing Phase II clinical trial of savolitinib in patients with papillary renal cell carcinoma PRCC at the 2017 Genitourinary Cancers Symposium sponsored by the American Society of Clinic..

Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Wednesday, February 15, 2017

Theratechnologies Inc Theratechnologies TSX TH announced today that additional secondary efficacy and safety endpoint results from the 24week ibalizumab Phase III trial TMB301 were presented at a latebreaker session at the Conference on Retroviruses and Opportunistic Infections CROI 2017 Preliminary..

Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral anti-arrhythmic budiodarone

Tuesday, February 14, 2017

Armetheon Inc a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases today announced the issuance on January 24 2017 by the US Patent and Trademark Office USPTO of a new patent covering the company39s novel oral antiarrhythmic budiodarone the only known ..

MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20

Tuesday, February 14, 2017

MabVax Therapeutics Holdings Inc a clinical stage immunooncology drug development company today announced results from a preclinical study evaluating the potential benefits of using MabVax39s HuMab5B1antibody MVT5873 currently in Phase I clinical trials for the treatment of metastatic pancreatic can..

Under the patronage of H. H. Sheikh Hamdan bin Rashid al Maktoum Award for Medical Sciences, 4TS International Conference 2017

Monday, February 13, 2017

Under the patronage of HH Sheikh Hamdan bin Rashid al Maktoum Award for Medical Sciences 4TS International Conference 2017will take place on 16thFebruary at Conrad Hotel Dubai The 4TS International Conference is being organized in collaboration with the International Society of Endovascular Special..

Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone

Friday, February 10, 2017

Neurocrine Biosciences Inc and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America ONGENTYS opicapone is a oncedaily peripherallyacting highlyselective catecholOmethyltransferase inhibitor COMT inhi..

Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301

Friday, February 10, 2017

Acorda Therapeutics Inc today announced Phase 3 clinical data of CVT301 showing a statistically significant improvement in motor function in people with Parkinsons disease experiencing OFF periods CVT301 is an investigational inhalable formulation of levodopa Ldopa It is being studied as a treatment..

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies

Friday, February 10, 2017

RepliCel Life Sciences Inc a clinical stage regenerative medicine company developing unique biologic products for pattern baldness and thinning hair aging and sundamaged skin and chronic tendon degeneration today announced the granting of two patents in Europe related to its multineedle dermal injec..

Newfound Effect of Cancer Drug May Expand its Use

Friday, February 10, 2017

A drug first designed to prevent cancer cells from multiplying has a second effect it switches immune cells that turn down the body39s attack on tumors back into the kind that amplify it This is the finding of a study led by researchers from NYU Langone Medical Center and published recently in Cance..